News und Analysen
Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
Investors view quarterly updates from clinical-stage biotechs in a much different way from how they view those of other companies. When Celldex Therapeutics (NASDAQ: CLDX) reported its first-quarter
Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum
Investors view quarterly updates from clinical-stage biotechs in a much different way from how they view those of other companies. When Celldex Therapeutics (NASDAQ: CLDX) reported its first-quarter
Why BeiGene Soared 56.6% In July
After inking a collaboration agreement with biotech powerhouse Celgene (NASDAQ: CELG), shares in BeiGene Ltd. (NASDAQ: BGNE) rocketed 56.6% higher last month, according to S&P Global Market
Why BeiGene Soared 56.6% In July
After inking a collaboration agreement with biotech powerhouse Celgene (NASDAQ: CELG), shares in BeiGene Ltd. (NASDAQ: BGNE) rocketed 56.6% higher last month, according to S&P Global Market
Why Amedisys Shares Slumped 24.6% in July
Amedisys Inc. (NASDAQ: AMED) shares lost nearly 25% of their value last month, according to S&P Global Market Intelligence. The drop was caused by word that the the federal government's Centers for
The Key Reason Alexion Pharmaceuticals, Inc. Vaulted 13% Higher in July
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a biotech company with a keen focus on developing therapies to treat ultra-rare diseases, moved steadily higher by 13% during the month of July
The Key Reason Alexion Pharmaceuticals, Inc. Vaulted 13% Higher in July
Shares of Alexion Pharmaceuticals (NASDAQ: ALXN), a biotech company with a keen focus on developing therapies to treat ultra-rare diseases, moved steadily higher by 13% during the month of July
MyoKardia Inc. Is on the Rise Again Today -- Here's Why
After a monster run-up on Monday, MyoKardia Inc. (NASDAQ: MYOK) climbed another 145.9% as of 3:30 p.m. during Tuesday's session. It seems investors still giddy about positive clinical trial data
Why FibroGen Inc Skyrocketed Higher Today
FibroGen (NASDAQ: FGEN) is up nearly 50% at 1:10 p.m. Tuesday after releasing positive data from its phase 2 trial testing pamrevlumab in patients with a lung disease called idiopathic pulmonary
Here's What's Pushing Up Esperion Therapeutics Inc. Today
Shares of Esperion Therapeutics Inc. (NASDAQ: ESPR), a clinical-stage biotech focused on reducing cholesterol, popped up again this morning in response to top-line clinical trial results for its lead
Here's Why Inovio Pharmaceuticals, Inc. Sank 30.8% in July
Shares of Inovio Pharmaceuticals (NASDAQ: INO), a clinical-stage biotech focused on DNA immunotherapies and vaccines, fell by nearly a third in July, according to data from S&P Global Market
Here's Why Coherus Biosciences Rose as Much as 22.2% Today
Shares of generic biologics developer Coherus Biosciences (NASDAQ: CHRS) rose over 22% today after the the company announced second-quarter 2017 financial results and the filing of a petition to
Here's Why Coherus Biosciences Rose as Much as 22.2% Today
Shares of generic biologics developer Coherus Biosciences (NASDAQ: CHRS) rose over 22% today after the the company announced second-quarter 2017 financial results and the filing of a petition to
Here's Why Coherus Biosciences Rose as Much as 22.2% Today
Shares of generic biologics developer Coherus Biosciences (NASDAQ: CHRS) rose over 22% today after the the company announced second-quarter 2017 financial results and the filing of a petition to
Here's Why Editas Medicine Rose as Much as 15.9% Monday
Shares of gene editing leader Editas Medicine (NASDAQ: EDIT) rose nearly 16% Monday on heavy trading volume, most of which occurred shortly after the market opened. The number of shares traded in the
The 1 Word in GW Pharmaceuticals' Q3 Update That Disappointed Investors
When GW Pharmaceuticals (NASDAQ: GWPH) announced its fiscal third-quarter results on Monday, the company provided plenty of information about its performance during the quarter. There were at least
BOIRON : Déclaration mensuelle des droits de vote au 31 juillet 2017
Le 8 août 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
Why Align Technology's Shares Soared 11.4% In July
After Align Technology (NASDAQ: ALGN) reported case shipments had notched another quarterly increase, the company's shares climbed 11.4% in July, according to S&P Global Market Intelligence. Growing
Why Align Technology's Shares Soared 11.4% In July
After Align Technology (NASDAQ: ALGN) reported case shipments had notched another quarterly increase, the company's shares climbed 11.4% in July, according to S&P Global Market Intelligence. Growing
Why Align Technology's Shares Soared 11.4% In July
After Align Technology (NASDAQ: ALGN) reported case shipments had notched another quarterly increase, the company's shares climbed 11.4% in July, according to S&P Global Market Intelligence. Growing
What's Behind TG Therapeutics Inc.'s 14.4% Rally in July?
Shares of TG Therapeutics Inc. (NASDAQ: TGTX) gained 14.4% in July, according to data from S&P Global Market Intelligence, despite a lack of positive announcements. It doesn't take much to move a
What's Behind TG Therapeutics Inc.'s 14.4% Rally in July?
Shares of TG Therapeutics Inc. (NASDAQ: TGTX) gained 14.4% in July, according to data from S&P Global Market Intelligence, despite a lack of positive announcements. It doesn't take much to move a
Here's Why Array BioPharma Inc. Fell 13.7% in July
Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.Here's a review of the two company
Here's Why Array BioPharma Inc. Fell 13.7% in July
Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.Here's a review of the two company
Here's Why Array BioPharma Inc. Fell 13.7% in July
Shares of Array BioPharma (NASDAQ: ARRY), a cancer-focused clinical-stage biotech, dropped nearly 14% in July, according to data from S&P Global Market Intelligence.Here's a review of the two company